期刊文献+

胸痹心血瘀阻证、痰阻心脉证与亚甲基四氢叶酸还原酶基因C 677T多态性的相关性研究 被引量:3

下载PDF
导出
摘要 目的:通过对心血瘀阻证、痰阻心脉证胸痹患者行基因测序,观察MTHFR基因多态性,分析2种证型与MTHFR基因型的相关性及其在不同基因型中的分布情况,并进一步探讨中医证型、MTHFR基因型、血Hcy水平对冠状动脉狭窄程度及预后的评估作用。方法:采取前瞻性的调查研究方法,选取符合中、西医诊断标准的患者209例,收集相关资料,建立数据库,采用SPSS 19.0统计软件,分析心血瘀阻证、痰阻心脉证与MTHFR基因型之间的相关性。结果:胸痹心血瘀阻证、痰阻心脉证与血Hcy水平、MTHFR基因型均具有相关性(P<0.05),且MTHFR基因型与血Hcy水平显著相关(P<0.01)。2组中医证型在CC基因型中的分布具有显著性差异(P<0.05),在CT、TT基因型中的分布无统计学差异(P>0.05)。2组中医证型、MTHFR基因型、血Hcy水平不是MACE事件的独立相关因素(P>0.05)。结论:胸痹心血瘀阻证、痰阻心脉证与MTHFR基因型具有相关性,且CC基因型更倾向于在心血瘀阻证中表达;中医证型、MTHFR基因型、血Hcy水平尚不能够用于评估冠状动脉狭窄程度及短期内心血管不良事件的发生率。
出处 《江苏中医药》 CAS 2017年第8期19-22,共4页 Jiangsu Journal of Traditional Chinese Medicine
  • 相关文献

参考文献1

二级参考文献24

  • 1李小鹰.阿司匹林在动脉硬化性心血管疾病中的临床应用:中国专家共识(2005)[J].中华心血管病杂志,2006,34(3):281-284. 被引量:193
  • 2Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines(Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol,2002, 40(7) :1366-1374.
  • 3Bertrand ME, Simoons ML, Fox KA, et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J,2002,23 ( 23 ) : 1809 -1840.
  • 4Erhardt L, Herlitz J, Bossaert L, et al. Task force on the management of chest pain. Eur Heart J, 2002, 23 ( 15 ) : 1153-1176.
  • 5CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet, 1996, 348(9038) :1329-1339.
  • 6Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med, 2001 , 345 ( 7 ) :494-502.
  • 7Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet, 2001, 358(9281):527-533.
  • 8Simoons ML, GUSTO IV-ACS Investigators. Effect of glycopmtein Ⅱb/Ⅲa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation:the GUSTO IV-ACS randomised trial. Lancet, 2001,357(9272) :1915-1924.
  • 9Platlat Receptor Inhibitor in Ischemic Syndrome Management(PRISM) study investigator. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management ( PRISM )Study Investigators. N Engl J Med, 1998, 338(21 ) :1498-1505.
  • 10Platlat Receptor Inhibitor in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms(PRISM-PLUS) study investigator. Inhibition of the platelet giycoprotein Ⅱb/Ⅲa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med,1998, 338(21) :1488-1497.

共引文献2124

同被引文献62

引证文献3

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部